Results 241 to 250 of about 106,748 (296)
Circulating CD20-positive extracellular vesicles impair rituximab efficacy and predict outcomes in diffuse large B-cell lymphoma. [PDF]
Blood Cancer JPark B +5 more
europepmc +1 more source
Target-Specific Dermatological Adverse Event Reporting With T-Cell-Engaging Bispecific Antibodies: A Pharmacovigilance Analysis of FAERS and Canada Vigilance, 2016-2026. [PDF]
Cancer MedMandal S, Maji M, Dhali A.
europepmc +1 more source
Immunotherapy with anti-CD20 compounds
Seminars in Cancer Biology, 2003 The B-cell surface antigen CD20 is currently the prime target for near-selective treatment of mature B-cell malignancies and a range of reactive B-cell associated disorders (including virus-associated lymphoproliferation or autoimmune conditions). CD20 is strongly and homogeneously expressed on the majority of mature B-cell neoplasms except chronic ...
von Schilling, C +1 more
openaire +3 more sources
CD20: A target antigen for immunotherapy of autoimmune diseases [PDF]
Autoimmunity Reviews, 2005 This article reviews the role of CD20 antigen in B cell function and the effectiveness and limits of passive immunotherapy with anti-CD20 monoclonal antibody (Rituximab) in the treatment of autoimmune (or immune-mediated) diseases.
Federico Perosa +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Engineering CD20 CARs with a Twist
Cancer Immunology Research, 2023CD20 is highly expressed in several types of B-cell lymphoma and is an intuitive target for chimeric antigen receptor (CAR) T-cell therapy. However, with conventional approaches, it has been challenging to provide CD20 CAR designs that confer efficacy in preclinical models and in clinical trials.
Lukas Scheller, Michael Hudecek
openaire +2 more sources